[2-(4-bromo-methylphenyl)ethoxy]-tert-butyldiphenylsilane | 701911-43-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(4-bromo-methylphenyl)ethoxy]-tert-butyldiphenylsilane
• 英文别名: 4-[2-(tert-butyldiphenylsilyloxy)ethyl]benzyl bromide；2-[4-(bromomethyl)phenyl]ethoxy-tert-butyl-diphenylsilane
• CAS: 701911-43-5
• 化学式: C₂₅H₂₉BrOSi
• 分子量: 453.494
• InChiKey: BTJFRCHACCONQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [2-(4-bromo-methylphenyl)ethoxy]-tert-butyldiphenylsilane 在 4-二甲氨基吡啶 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 4-[2-[[4-[2-[Tert-butyl(diphenyl)silyl]oxyethyl]phenyl]methoxymethyl]-2-[[4-[2-[(3,4-dimethoxyphenyl)methoxy]ethyl]phenyl]methoxymethyl]-3-[[4-[2-(oxan-2-yloxy)ethyl]phenyl]methoxy]propoxy]-4-oxobutanoic acid
  参考文献：
  名称：

  具有灵活但预先组织的几何形状的高功能化三足肽的固体支持合成：走向潜在的丝氨酸蛋白酶模拟物

  摘要：

  三足支架 1 已用于合成丝氨酸蛋白酶模拟库的代表性成员，在中央核心上拥有三个独立的功能化肽链。每条肽链都包含在丝氨酸蛋白酶 α-胰凝乳蛋白酶的活性位点中发现的经典催化三联体（丝氨酸、组氨酸和天冬氨酸）的一个残基。新型三脚架设计的一个特点是其本质上灵活但预先组织的结构，正如从分子建模研究中推断出来的。对合适的支架和侧链保护基团的选择进行了深入研究和优化，以确保完全正交。

  DOI：

  10.1002/ejoc.200600145
• 作为产物：
  描述：

  对甲基苯乙酸 在 偶氮二异丁腈 、 dimethyl sulfide borane 、 溴 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 四氯化碳 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.08h， 生成 [2-(4-bromo-methylphenyl)ethoxy]-tert-butyldiphenylsilane
  参考文献：
  名称：

  具有灵活但预先组织的几何形状的高功能化三足肽的固体支持合成：走向潜在的丝氨酸蛋白酶模拟物

  摘要：

  三足支架 1 已用于合成丝氨酸蛋白酶模拟库的代表性成员，在中央核心上拥有三个独立的功能化肽链。每条肽链都包含在丝氨酸蛋白酶 α-胰凝乳蛋白酶的活性位点中发现的经典催化三联体（丝氨酸、组氨酸和天冬氨酸）的一个残基。新型三脚架设计的一个特点是其本质上灵活但预先组织的结构，正如从分子建模研究中推断出来的。对合适的支架和侧链保护基团的选择进行了深入研究和优化，以确保完全正交。

  DOI：

  10.1002/ejoc.200600145

文献信息

• A Pentaerythritol-Based Molecular Scaffold for Solid-Phase Combinatorial Chemistry
  作者：Nadia Farcy、Hilde De Muynck、Annemieke Madder、Noël Hosten、Pierre J. De Clercq

  DOI：10.1021/ol016980p

  日期：2001.12.1

  A convergent synthesis has been developed for the preparation of solid-phase bound construct 1, consisting of an orthogonally protected trifunctional core structure that is attached to TentaGel via a photocleavable linker. [structure: see text]

  已经开发了收敛性合成用于制备固相结合的构建体1，该构建体1包括通过光可裂解的接头与TentaGel连接的正交保护的三官能核心结构。[结构：见文字]
• 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Yonekubo Shigeru

  公开号：US20090074738A1

  公开（公告）日：2009-03-19

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等的药物。该化合物是一种1-取代-3-(β-D-葡萄糖苷基)氮杂环化合物，其通式表示为(I)，其前药，或其药学上可接受的盐，或其水合物或溶剂化物；包含该化合物的SGLT抑制剂；包含该化合物的制药组合物和药物组合制剂。在该式中，A代表烷基或烯烃基；B代表单键，—O—，—S—或—NH—；C代表可选择取代的芳基或杂芳基；Q独立地表示氢原子或取代基结合的碳原子或氮原子。
• 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07750145B2

  公开（公告）日：2010-07-06

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等药物。它是一种1-取代-3-（β-D-葡萄糖苷基）含氮杂环化合物，代表通式（I），其前药，或其药学上可接受的盐，或其水合物或溶剂化物；含有SGLT抑制剂的化合物；含有该化合物的制药组合物。在该式中，A代表烷基或烯基；B代表单键，-O-，-S-或-NH-；C代表可选取代的芳基或杂环芳基；Q独立地表示氢原子或取代基连接的碳原子或氮原子。
• 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813611B1

  公开（公告）日：2014-10-01
• New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents
  作者：Wenhua Chu、Jinbin Xu、Dong Zhou、Fanjie Zhang、Lynne A. Jones、Kenneth T. Wheeler、Robert H. Mach

  DOI：10.1016/j.bmc.2008.12.025

  日期：2009.2

  A series of N-substituted 9-azabicyclo[3.3.1] nonan-3 alpha-yl phenylcarbamate analogs were synthesized. Among them, WC-26 and WC-59 were identified as the most potent sigma(2) receptor ligands (K-i = 2.58 and 0.82 nM, respectively) with high selectivity against sigma(1) (K-i of sigma(1)/sigma(2) ratio = 557 and 2087, respectively). [F-18] WC-59 was radiolabeled via a nucleophilic substitution of a mesylate precursor by [F-18]fluoride and in vitro direct binding studies of [F-18]WC-59 were conducted using membrane preparations from murine EMT-6 solid breast tumors. The results indicate that [F-18]WC-59 binds specifically to sigma(2) receptors in vitro (K-d = similar to 2 nM). Biodistribution studies of [F-18]WC-59 in EMT-6 tumor-bearing mice indicated that the tracer was a less suitable candidate for clinical imaging studies than existing F-18 labeled sigma(2) receptor ligands. The ability of WC-26 to enhance the cytotoxic effects of the chemotherapy drug, doxorubicin, was evaluated in cell culture using the mouse breast tumor EMT-6 and the human tumor MDA-MB435. WC-26 greatly increased the ability of doxorubicin to kill these two tumor cell lines in vitro. These results indicate that WC-26 is potentially a useful chemosensitizer for the treatment of cancer when combined with conventional chemotherapeutics. (c) 2009 Elsevier Ltd. All rights reserved.